Research programme: cancer vaccines - Geovax

Drug Profile

Research programme: cancer vaccines - Geovax

Alternative Names: MVA-VLP cancer vaccine - GeoVax Labs; MVA-VLP-MUC1

Latest Information Update: 04 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GeoVax Labs
  • Developer GeoVax Labs; University of North Carolina at Chapel Hill; University of Pittsburgh
  • Class Cancer vaccines; DNA vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants; Mucin 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 30 Aug 2017 Preclinical trials in Cancer (Prevention) in USA (Parenteral)
  • 11 Nov 2016 GeoVax and ViaMune co-develop cancer vaccines in USA
  • 09 Feb 2016 GeoVax labs and University of Pittsburgh agree to co-develop cancer vaccines in USA for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top